Harmony Biosciences

HARMONY BIOSCIENCES SHOWCASES THE NEWEST PATIENTS AT THE HEART AND PROGRESS AT THE HEART AWARD RECIPIENTS

by

PLYMOUTH MEETING, Pa., Oct. 26, 2023 /PRNewswire/ — Harmony Biosciences Holdings, Inc. (“Harmony”) (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients with rare neurological diseases, has selected the latest round of nonprofit organizations for its Patients at the Heart and Progress at the Heart awards. These awards provide funding support … Read more

HARMONY BIOSCIENCES COMPLETES ENROLLMENT OF PHASE 3 REGISTRATIONAL INTUNE STUDY IN IDIOPATHIC HYPERSOMNIA

by

PLYMOUTH MEETING, Pa., May 25, 2023 /PRNewswire/ — Harmony Biosciences Holdings, Inc. (“Harmony”) (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients with rare neurological diseases, today announced that its Phase 3 registrational INTUNE study evaluating the safety and efficacy of pitolisant in adult patients with idiopathic hypersomnia (IH) has … Read more